Q-omics provides the consensus-scored RASGRP1 profile across patient tissues and cancer cell-line models. RASGRP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RASGRP1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, RASGRP1 RNA expression shows 19,319 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KICH, and UVM as cancer lineages where RASGRP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASGRP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASGRP1 survival associations across molecular data types. RASGRP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASGRP1 RNA expression–survival associations across cancer types. High RASGRP1 expression shows unfavorable associations in KIRP and UVM, but favorable associations in SKCM, BRCA, HNSC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RASGRP1 RNA expression.
This table summarizes RASGRP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RASGRP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASGRP1 shows lower tumor expression in KICH, KIRP, LUSC and BRCA and higher tumor expression in BRCA and CHOL. The KICH box plot shows higher RASGRP1 RNA expression in normal versus tumor tissue (log2 FC = −1.928, t-test p < 0.001).
This table shows molecular features associated with RASGRP1 in patient tissues and cancer cell lines. In patient samples, RASGRP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RASGRP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
